We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+6.14%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.52B
AUM Growth
+$385M
Cap. Flow
+$3.2M
Cap. Flow %
0.04%
Top 10 Hldgs %
34.42%
Holding
155
New
17
Increased
44
Reduced
30
Closed
23

Top Buys

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$102M
2
CFN
CAREFUSION CORPORATION
CFN
+$68.7M
3
BMY icon
Bristol-Myers Squibb
BMY
+$60.2M
4
SHPG
Shire pic
SHPG
+$55.3M
5
TRNX
TORNIER N V SHARES (NLD)
TRNX
+$54M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$146M
2
AGN
Allergan Inc
AGN
+$113M
3
PRTA icon
Prothena Corp
PRTA
+$72.4M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$63M
5
XLRN
Acceleron Pharma
XLRN
+$56.7M

Sector Composition

Rank Sector Weight
1 Healthcare 82.59%
2 Financials 0.08%
3 Technology 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NXTM
76
DELISTED
NxStage Medical Inc.
NXTM
$11.4M 0.13%
795,200
-1,317,800
-62% -$17.2M
NUVA
77
DELISTED
NuVasive, Inc.
NUVA
$11.2M 0.13%
316,000
– –
XOMA
78
DELISTED
Xoma
XOMA
$11.2M 0.13%
121,850
– –
INSM icon
79
Insmed
INSM
$22.5B
$10.8M 0.13%
+538,500
New +$7.97M
RDHL
80
Redhill Biopharma
RDHL
$4.26M
$10.6M 0.12%
606
-26
-4% -$413K
MRGE
81
DELISTED
MERGE HEALTHCARE INC COM STK (WI)
MRGE
$10.5M 0.12%
4,628,500
– –
AMBI
82
DELISTED
Ambit Biosciences Corp
AMBI
$10.3M 0.12%
1,490,769
– –
PTX
83
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$10.2M 0.12%
113,060
-106,790
-49% -$6.54M
NSPR icon
84
InspireMD
NSPR
$32.3M
$10M 0.12%
1
– –
FRX
85
DELISTED
FOREST LABORATORIES INC
FRX
$9.6M 0.11%
97,000
+3,000
+3% +$280K
XNCR icon
86
Xencor
XNCR
$1.44B
$9.32M 0.11%
801,700
– –
QCOR
87
CALL
DELISTED
QUESTCOR PHARMA INC
QCOR
$9.25M 0.11%
100,000
+50,000
+100% +$4.28M
SVA
88
DELISTED
Sinovac Biotech, Ltd
SVA
$9.24M 0.11%
1,637,500
– –
ALIM
89
DELISTED
Alimera Sciences
ALIM
$8.97M 0.11%
100,000
– –
ARQL
90
DELISTED
Arqule Inc
ARQL
$8.84M 0.1%
5,702,000
– –
STJ
91
CALL
DELISTED
St Jude Medical
STJ
$8.66M 0.1%
+125,000
New +$8.1M
HZNP
92
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$8.64M 0.1%
546,000
+350,000
+179% +$5M
VIRX
93
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$7.82M 0.09%
5,714
– –
ZTS icon
94
Zoetis
ZTS
$33.1B
$7.39M 0.09%
229,000
+8,000
+4% +$245K
ABT icon
95
Abbott
ABT
$191B
$7.36M 0.09%
180,000
+6,000
+3% +$236K
VNDA icon
96
Vanda Pharmaceuticals
VNDA
$301M
$7.36M 0.09%
455,000
-7,400
-2% -$98.6K
LAB icon
97
CALL
Standard BioTools
LAB
$325M
$7.35M 0.09%
250,000
+150,000
+150% +$4.81M
AET
98
DELISTED
Aetna Inc
AET
$6.49M 0.08%
80,000
+17,000
+27% +$1.29M
ELV icon
99
Elevance Health
ELV
$82.9B
$6.46M 0.08%
+60,000
New +$6.18M
CSII
100
DELISTED
Cardiovascular Systems, Inc.
CSII
$6.42M 0.08%
+206,000
New +$5.94M
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q2 2014 Portfolio in Review

As of Q2 2014, OrbiMed held 155 positions worth $8.52B, up 4.7% from $8.13B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed's Q2 2014 filing shows 17 new, 44 increased, 30 reduced and 23 closed positions. Its largest new stake was Alkermes: 433,300 shares worth $21.8M. The largest sale was Gilead Sciences, an estimated $146M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 83% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q2 2014 buy was Alkermes: 433,300 shares worth $21.8M.
  • OrbiMed added most to Ironwood Pharmaceuticals in Q2 2014, an estimated $102M increase.
  • OrbiMed's biggest Q2 2014 reduction was Gilead Sciences, cutting an estimated $146M.
  • OrbiMed fully exited Prothena Corp in Q2 2014, selling an estimated $72.4M.
  • OrbiMed's ten largest holdings make up 34% of its $8.52B portfolio in Q2 2014.
  • OrbiMed opened 17 new positions and closed 23 in Q2 2014.
  • OrbiMed's portfolio value rose 4.7% quarter-over-quarter to $8.52B.

Based on OrbiMed's 13F filing for Q2 2014, filed 14 Aug 2014.